Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer
- 23 July 2019
- journal article
- research article
- Published by Elsevier BV in Auris Nasus Larynx
- Vol. 46 (6), 896-901
- https://doi.org/10.1016/j.anl.2019.02.005
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature ReviewInternal Medicine, 2018
- Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumabJapanese Journal of Clinical Oncology, 2017
- Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung CancerInternal Medicine, 2017
- Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor]Endocrine Journal, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckThe New England Journal of Medicine, 2016
- Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2016
- Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapyThe Journal of Dermatology, 2016
- Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patientThe Journal of Dermatology, 2016
- Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanomaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2016
- Nivolumab-induced hypophysitis in a patient with advanced malignant melanomaEndocrine Journal, 2016